Lipopolysaccharides-Mediated Increase in Glucose-Stimulated Insulin Secretion: Involvement of the GLP-1 Pathway

  1. Jacques Grober1
  1. 1INSERM UMR866-LabEx LipSTIC, Faculté de Médecine, Université de Bourgogne, Dijon, France
  2. 2INSERM Unité 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse, Université Paul Sabatier, Toulouse, France
  3. 3Department of Medicine, Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
  4. 4Centre Hospitalier Universitaire Dijon, Hôpital du Bocage, Dijon, France
  1. Corresponding author: Jacques Grober, jacques.grober{at}, or Laurent Lagrost, laurent.lagrost{at}


Lipopolysaccharides (LPS) of the cell wall of gram–negative bacteria trigger inflammation, which is associated with marked changes in glucose metabolism. Hyperglycemia is frequently observed during bacterial infection and it is a marker of a poor clinical outcome in critically ill patients. The aim of the current study was to investigate the effect of an acute injection or continuous infusion of LPS on experimentally induced hyperglycemia in wild-type and genetically engineered mice. The acute injection of a single dose of LPS produced an increase in glucose disposal and glucose-stimulated insulin secretion (GSIS). Continuous infusion of LPS through mini-osmotic pumps was also associated with increased GSIS. Finally, manipulation of LPS detoxification by knocking out the plasma phospholipid transfer protein (PLTP) led to increased glucose disposal and GSIS. Overall, glucose tolerance and GSIS tests supported the hypothesis that mice treated with LPS develop glucose-induced hyperinsulinemia. The effects of LPS on glucose metabolism were significantly altered as a result of either the accumulation or antagonism of glucagon-like peptide 1 (GLP-1). Complementary studies in wild-type and GLP-1 receptor knockout mice further implicated the GLP-1 receptor–dependent pathway in mediating the LPS-mediated changes in glucose metabolism. Hence, enhanced GLP-1 secretion and action underlies the development of glucose-mediated hyperinsulinemia associated with endotoxemia.

  • Received June 9, 2013.
  • Accepted October 30, 2013.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See for details.

| Table of Contents

This Article

  1. Diabetes vol. 63 no. 2 471-482
  1. All Versions of this Article:
    1. db13-0903v1
    2. 63/2/471 most recent